Strategy for utilization of new antiepileptic drugs.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Ben Menachem Elinor 1945) > Strategy for utiliz...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		03319naa a2200589 4500
001		oai:gup.ub.gu.se/80754
003		SwePub
008		240528s2008 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://gup.ub.gu.se/publication/807542 URI
024	7	a https://doi.org/10.1097/WCO.0b013e3282f827f92 DOI
040		a (SwePub)gu
041		a eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Ben-Menachem, Elinor,d 1945u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation4 aut0 (Swepub:gu)xbenel
245	1 0	a Strategy for utilization of new antiepileptic drugs.
264	1	c 2008
520		a PURPOSE OF REVIEW: The paper reviews strategies to incorporate new antiepileptic drugs into the treatment arsenal for patients with epilepsy. RECENT FINDINGS: Ten new antiepileptic drugs have been developed in the last two decades, making selection of optimal therapy complex; they have not been shown to have better efficacy but generally seem to be better tolerated. Newer antiepileptic drugs offer new opportunities to patients who have not had a favorable response to the old ones. Many new antiepileptic drugs exhibit a broad spectrum of activity while only one of the older ones (valproate) has a broad-spectrum profile. There are therefore more choices when trying to match treatment with epileptic seizures and syndromes. The side-effect profiles of the newer antiepileptic drugs differ from the older ones with fewer systemic reactions and better pharmacokinetics for the most part. SUMMARY: Comparative studies are needed to elucidate the specific weaknesses and strengths of each of the new antiepileptic drugs compared with the older ones. Most clinical trials do not help the physician in deciding drug, dose, or titration schedules. Thus the physician needs to understand efficacy spectrum and side-effect profiles of each new antiepileptic drug in order to be able to treat each patient optimally.
653		a Age Factors
653		a Aged
653		a Anticonvulsants
653		a administration & dosage
653		a adverse effects
653		a pharmacokinetics
653		a Brain
653		a drug effects
653		a metabolism
653		a physiopathology
653		a Child
653		a Drug Resistance
653		a physiology
653		a Epilepsy
653		a drug therapy
653		a metabolism
653		a physiopathology
653		a Female
653		a Humans
653		a Liver
653		a drug effects
653		a enzymology
653		a Neuropharmacology
653		a methods
653		a trends
653		a Patient Selection
653		a Pregnancy
653		a Sex Factors
653		a Treatment Outcome
710	2	a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering4 org
773	0	t Current opinion in neurologyg 21:2, s. 167-72q 21:2<167-72x 1350-7540
856	4 8	u https://gup.ub.gu.se/publication/80754
856	4 8	u https://doi.org/10.1097/WCO.0b013e3282f827f9

Hitta via bibliotek

Current opinion in neurology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Ben-Menachem, El ...

Artiklar i publikationen: Current opinion ...

Av lärosätet: Göteborgs universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se